scholarly journals Effectiveness of collagen/oxidised regenerated cellulose/silver-containing composite wound dressing for the treatment of medium-depth split-thickness skin graft donor site wounds in multi-morbid patients: a prospective, non-comparative, single-centre stud

2016 ◽  
Vol 14 (5) ◽  
pp. 791-800 ◽  
Author(s):  
Alexander Konstantinow ◽  
Tatjana V Fischer ◽  
Johannes Ring
2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Sukhontha Hasatsri ◽  
Apichai Angspatt ◽  
Pornanong Aramwit

We developed the novel silk fibroin-based bilayered wound dressing for the treatment of partial thickness wounds. And it showed relevant characteristics and accelerated the healing of full-thickness wounds in a rat model. This study is the clinical evaluation of the bilayered wound dressing to confirm its safety and efficacy for the treatment of split-thickness skin donor sites. The safety test was performed using a patch model and no evidence of marked and severe cutaneous reactions was found. The efficacy test of the bilayered wound dressing was conducted on 23 patients with 30 split-thickness skin graft donor sites to evaluate healing time, pain score, skin barrier function, and systemic reaction in comparison to Bactigras. We found that the healing time of donor site wounds treated with the bilayered wound dressing (11 ± 6 days) was significantly faster than those treated with Bactigras (14 ± 6 days) (p=10-6). The wound sites treated with the bilayered wound dressing showed significantly less pain and more rapid skin functional barrier recovery than those treated with Bactigras (p=10-5). Therefore, these results confirmed the clinical safety and efficacy of the bilayered wound dressing for the treatment of split-thickness skin graft donor sites.


Burns ◽  
2021 ◽  
Author(s):  
Malachy Asuku ◽  
Tzy-Chyi Yu ◽  
Qi Yan ◽  
Elaine Böing ◽  
Helen Hahn ◽  
...  

2003 ◽  
Vol 29 (2) ◽  
pp. 168-172
Author(s):  
AYKUT MISIRLIOGLU ◽  
SINEM EROGLU ◽  
NACI KARACAOGLAN ◽  
MITHAT AKAN ◽  
TAYFUN AKOZ ◽  
...  

2017 ◽  
Vol 5 (5) ◽  
pp. e1339 ◽  
Author(s):  
Brian P. Bradow ◽  
Geoffrey G. Hallock ◽  
Samuel P. Wilcock

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Alexandra Poinas ◽  
Pierre Perrot ◽  
Judith Lorant ◽  
Olivier Nerrière ◽  
Jean-Michel Nguyen ◽  
...  

Abstract Background Wound repair is one of the most complex biological processes of human life. Allogeneic cell-based engineered skin substitutes provide off-the-shelf temporary wound coverage and act as biologically active dressings, releasing growth factors, cytokines and extracellular matrix components essential for proper wound healing. However, they are susceptible to immune rejection and this is their major weakness. Thanks to their low immunogenicity and high effectiveness in regeneration, fetal skin cells represent an attractive alternative to the commonly used autologous and allogeneic skin grafts. Methods/design We developed a new dressing comprising a collagen matrix seeded with a specific ratio of active fetal fibroblasts and keratinocytes. These produce a variety of healing growth factors and cytokines which will increase the speed of wound healing and induce an immunotolerant state, with a slight inflammatory reaction and a reduction in pain. The objective of this study is to demonstrate that the use of this biological dressing for wound healing at the split-thickness skin graft (STSG) donor site, reduces the time to healing, decreases other co-morbidities, such as pain, and improves the appearance of the scar. This investigation will be conducted as part of a randomized study comparing our new biological dressing with a conventional treatment in a single patient, thus avoiding the factors that may influence the healing of a graft donor site. Discussion This clinical trial should enable the development of a new strategy for STSG donor-wound healing based on a regenerative dressing. The pain experienced in the first few days of STSG healing is well known due to the exposure of sensory nerve endings. Reducing this pain will also reduce analgesic drug intake and the duration of sick leave. Our biological dressing will meet the essential need of surgeons to “re-crop” from existing donor sites, e.g., for thermal-burn patients. By accelerating healing, improving the appearance of the scar and reducing pain, we hope to improve the conditions of treatment for skin grafts. Trial registration ClinicalTrials.gov, ID: NCT03334656. Registered on 7 November 2017.


2013 ◽  
Vol 34 (2) ◽  
pp. e80-e86 ◽  
Author(s):  
Sigrid Blome-Eberwein ◽  
Michael Abboud ◽  
Daniel D. Lozano ◽  
Rohit Sharma ◽  
Sherrine Eid ◽  
...  

Burns ◽  
2008 ◽  
Vol 34 (7) ◽  
pp. 1011-1014 ◽  
Author(s):  
Fatih Uygur ◽  
Rahmi Evınc ◽  
Ersin Ulkur ◽  
Bahattin Celıkoz

1974 ◽  
Vol 14 (2) ◽  
pp. 163-167 ◽  
Author(s):  
GARY D. FRIEDMAN ◽  
ANGELO CAPOZZI ◽  
VINCENT R. PENNISI

2012 ◽  
Vol 123 (2) ◽  
pp. 496-498 ◽  
Author(s):  
Hernan Goldsztein ◽  
Stuart Ort ◽  
Joseph B. Roberson ◽  
John Reinisch

Sign in / Sign up

Export Citation Format

Share Document